BioCentury | Dec 22, 2017
Financial News

JHL delisting from TPEx

...JHL Biotech Inc. (TPEx-E:6540), Zhubei, Taiwan Jaime De Leon JHL1101 Genentech Inc. JHL Biotech Inc. Medigen Biotechnology Corp. PharmaEngine Inc. Roche Senhwa Biosciences Inc. TaiGen Biopharmaceuticals Holdings Ltd. CD20...
BioCentury | Dec 21, 2017
Financial News

JHL delisting from TPEx

...of the candidates next year. Jaime De Leon dornase alfa Herceptin JHL1101 Pulmozyme Rituxan rituximab Genentech Inc. JHL Biotech Inc. Medigen Biotechnology Corp. PharmaEngine Inc. Roche Senhwa Biosciences Inc. TaiGen Biopharmaceuticals Holdings Ltd....
BioCentury | Mar 3, 2017
Company News

Second Ascletis HCV therapy gets expedited CFDA review

...Gilead Sciences Inc. (NASDAQ:GILD); Bristol-Myers Squibb Co. (NYSE:BMY); AbbVie Inc. (NYSE:ABBV); Johnson & Johnson (NYSE:JNJ); TaiGen Biopharmaceuticals Holdings Ltd....
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
BioCentury | Dec 30, 2016
Company News

China accepts NDA for Ascletis' HCV candidate

...Gilead Sciences Inc. (NASDAQ:GILD); Bristol-Myers Squibb Co. (NYSE:BMY); AbbVie Inc. (NYSE:ABBV); Johnson & Johnson (NYSE:JNJ); TaiGen Biopharmaceuticals Holdings Ltd....
BioCentury | Nov 11, 2016
Company News

HEC, TaiGen deal

...Taigen will hold the balance. Based on results of Phase II testing of the combination, TaiGen...
...which TaiGen will hold a 40% stake in the newco and HEC will own 60%. TaiGen...
...HEC Pharm Group , Dongguan, China TaiGen Biopharmaceuticals Holdings Ltd. (TPex:4157), Taipei, Taiwan Business: Infectious Nora Weintraub DAG-181 NS5A inhibitor TG-2349 HEC Pharm Group TaiGen Biopharmaceuticals Holdings Ltd....
BioCentury | Oct 31, 2016
Company News

TaiGen, HEC launch cross-strait newco for HCV combo

...and give the newco Greater China rights to NS5A inhibitor yimitasvir ( DAG-181 ), and TaiGen...
...Taigen will hold the balance. Based on results of Phase II testing of the combination, TaiGen...
...which it will hold a 40% stake in the newco and HEC will own 60%. TaiGen...
BioCentury | Oct 3, 2016
Finance

ASH and others

...cancer PDUFA date 12/11/16 Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Plecanatide IBS-C Top-line Ph III data 4Q16 TaiGen Biopharmaceuticals Holdings Ltd....
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...NASDAQ:SGYP) Plecanatide Irritable bowel syndrome with constipation (IBS-C) Ph III data; submit NDA 3Q16; YE16 TaiGen Biopharmaceuticals Holdings Ltd....
BioCentury | Jul 11, 2016
Finance

Shedding red

...NASDAQ:BIIB) EC approves Alprolix eftrenonacog alfa to treat and prevent bleeding in hemophilia B patients TaiGen Biopharmaceuticals Holdings Ltd....
Items per page:
1 - 10 of 86
BioCentury | Dec 22, 2017
Financial News

JHL delisting from TPEx

...JHL Biotech Inc. (TPEx-E:6540), Zhubei, Taiwan Jaime De Leon JHL1101 Genentech Inc. JHL Biotech Inc. Medigen Biotechnology Corp. PharmaEngine Inc. Roche Senhwa Biosciences Inc. TaiGen Biopharmaceuticals Holdings Ltd. CD20...
BioCentury | Dec 21, 2017
Financial News

JHL delisting from TPEx

...of the candidates next year. Jaime De Leon dornase alfa Herceptin JHL1101 Pulmozyme Rituxan rituximab Genentech Inc. JHL Biotech Inc. Medigen Biotechnology Corp. PharmaEngine Inc. Roche Senhwa Biosciences Inc. TaiGen Biopharmaceuticals Holdings Ltd....
BioCentury | Mar 3, 2017
Company News

Second Ascletis HCV therapy gets expedited CFDA review

...Gilead Sciences Inc. (NASDAQ:GILD); Bristol-Myers Squibb Co. (NYSE:BMY); AbbVie Inc. (NYSE:ABBV); Johnson & Johnson (NYSE:JNJ); TaiGen Biopharmaceuticals Holdings Ltd....
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
BioCentury | Dec 30, 2016
Company News

China accepts NDA for Ascletis' HCV candidate

...Gilead Sciences Inc. (NASDAQ:GILD); Bristol-Myers Squibb Co. (NYSE:BMY); AbbVie Inc. (NYSE:ABBV); Johnson & Johnson (NYSE:JNJ); TaiGen Biopharmaceuticals Holdings Ltd....
BioCentury | Nov 11, 2016
Company News

HEC, TaiGen deal

...Taigen will hold the balance. Based on results of Phase II testing of the combination, TaiGen...
...which TaiGen will hold a 40% stake in the newco and HEC will own 60%. TaiGen...
...HEC Pharm Group , Dongguan, China TaiGen Biopharmaceuticals Holdings Ltd. (TPex:4157), Taipei, Taiwan Business: Infectious Nora Weintraub DAG-181 NS5A inhibitor TG-2349 HEC Pharm Group TaiGen Biopharmaceuticals Holdings Ltd....
BioCentury | Oct 31, 2016
Company News

TaiGen, HEC launch cross-strait newco for HCV combo

...and give the newco Greater China rights to NS5A inhibitor yimitasvir ( DAG-181 ), and TaiGen...
...Taigen will hold the balance. Based on results of Phase II testing of the combination, TaiGen...
...which it will hold a 40% stake in the newco and HEC will own 60%. TaiGen...
BioCentury | Oct 3, 2016
Finance

ASH and others

...cancer PDUFA date 12/11/16 Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Plecanatide IBS-C Top-line Ph III data 4Q16 TaiGen Biopharmaceuticals Holdings Ltd....
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...NASDAQ:SGYP) Plecanatide Irritable bowel syndrome with constipation (IBS-C) Ph III data; submit NDA 3Q16; YE16 TaiGen Biopharmaceuticals Holdings Ltd....
BioCentury | Jul 11, 2016
Finance

Shedding red

...NASDAQ:BIIB) EC approves Alprolix eftrenonacog alfa to treat and prevent bleeding in hemophilia B patients TaiGen Biopharmaceuticals Holdings Ltd....
Items per page:
1 - 10 of 86